ライフサイエンスコーパス: vascular access

1 venting infections associated with long-term vascular access.

2 e remaining venous site to achieve permanent vascular access.

3 sted all upper extremity sites for permanent vascular access.

4 ated hospitalizations were not attributed to vascular access.

5 wo complications were noted, nine related to vascular access.

6 g/dL, and an arteriovenous fistula as their vascular access.

7 starting hemodialysis predicted the type of vascular access.

8 88.2% patients used fistula as their vascular access.

9 s occurred in 4 patients and were related to vascular access.

10 is especially helpful in patients with poor vascular access.

11 of anatomical landmark (LM) versus US-guided vascular access.

12 vasation focused mainly on ensuring adequate vascular access.

13 catheters are considered "midway" regarding vascular access.

14 antigen (SLA), and (iii) those with failing vascular access.

15 ar tachycardia after at least one shock, and vascular access.

16 were restenosis, thrombosis, and failure of vascular access.

17 the role of indoxyl sulfate in hemodialysis vascular access.

18 elays in providing consent (4.4%), difficult vascular access (8.4%), difficulty crossing the lesion (

19 fellowship programs in the following areas: vascular access (98%), lung and pleural (74%), cardiac (

20 cess for starting hemodialysis (ie, incident vascular access), a key care quality metric for patients

21 Complications from vascular access account for 15% of hospital admissions a

22 Procedural and vascular-access adverse events occurred in 14 patients (

23 use, and all hospitalizations not related to vascular access) also did not differ significantly betwe

24 rology care accounted for 32.59% of incident vascular access and 62.00% of maturing vascular access u

25 prevention measures should include improved vascular access and CVC care.

26 s a composite end point including successful vascular access and deployment of the device and retriev

27 es and trials have advanced our knowledge of vascular access and different anticoagulation regimens.

28 unmet clinical need for novel techniques in vascular access and is driving innovation in vascular ac

29 rred for a third transplant due to decreased vascular access and progressive hypotension from uremic

30 can be selected depending on the quality of vascular access and the type of prosthesis used.

31 ity of RRT, delayed placement of a permanent vascular access, and delayed initiation of RRT.

32 preserve kidney function, early planning for vascular access, and education to support self-managemen

33 clude reduced procedural downtime, optimized vascular access, and enhanced therapeutic efficiency.

34 rapeutic procedures involving needles and/or vascular access, and often they do so in darkened rooms.

35 r general use with maintained visualization, vascular access, and shielding in routine cardiac cathet

36 Pharmacotherapy, vascular access, and the presentation and management of

37 Adults with nontraumatic OHCA, vascular access, and VF/VT anytime after >/=1 shock(s) w

38 methods, respectively); use of a fistula for vascular access; and measured single-pool Kt/V urea valu

39 The most common vascular access approach was transfemoral (4972 patients

40 Hemodialysis vascular accesses are prone to recurrent stenosis and th

41 grafts, an important option for hemodialysis vascular access, are prone to recurrent stenosis and thr

42 Type of permanent vascular access (arteriovenous fistula vs synthetic graf

43 to evaluate the associations between type of vascular access (arteriovenous fistula, arteriovenous gr

44 cessful creation and maintenance of reliable vascular access become a real challenge.

45 ents with advanced CKD who receive permanent vascular access before dialysis initiation are unclear.

46 galactosylceramide activated NKT1 cells with vascular access, but not LN or thymic NKT cells, resulti

47 Although vascular access buttons (VABs) offer significant advanta

48 Chronic vascular access can be maintained with minimal supervisi

49 or the administration of drugs and fluids if vascular access cannot be established.

50 d recommendations concerning the approach to vascular access care.

51 vascular access and is driving innovation in vascular access care.

52 .g., postoperative state, trauma, indwelling vascular access, certain medications).

53 garnered strong endorsement as the favoured vascular access choice for extended haemodialysis.

54 the clinical and economic effects of initial vascular access choice.

55 tment with antiplatelet agents, selection of vascular access, choice of coronary stents and antithrom

56 Patients were classified into one of three vascular access choices: maintain CVC, attempt fistula,

57 the treatment area and patency of the entire vascular access circuit.

58 Doppler ultrasound and then be assigned to a vascular access class.

59 ar access type 2 yr after the translation of vascular access clinical practice guideline statements i

60 a permanent pacemaker, 1 patient (5%) had a vascular access complication requiring endovascular repa

61 tients required early reinterventions: 8 for vascular access complication, 2 for endoleak correction,

62 e had transient diaphragmatic paralysis, one vascular access complication, and one had transient ST-s

63 mothorax, stroke, transient ischemic attack, vascular access complications (hemorrhage/hematoma, vasc

64 1, prior to radiofrequency application), and vascular access complications (n = 4).

65 Vascular access complications are a major cause of morbi

66 bidity and mortality associated with current vascular access complications highlights an unmet clinic

67 dize reporting of methods and definitions of vascular access complications in future clinical studies

68 frequent hemodialysis increases the risk of vascular access complications.

69 ore independently predicted a higher risk of vascular access complications.

70 lar access planning has been shown to reduce vascular access complications.

71 ic flashlight than with conventional US, and vascular access could be gained in a cadaver; the sonic

72 to the nephrologist and timely placement of vascular access could result in reduced utilization and

73 ining, P < 0.0001) and degree of emphasis on vascular access creation during training (AOR = 2.4 for

74 s with advanced CKD who received predialysis vascular access creation initiated dialysis within 2 yea

75 and dialysis-free survival for 2 years after vascular access creation.

76 nvestigation of this question, a prospective vascular access database was queried retrospectively to

77 tion to angiographic data on vascularity and vascular access, demonstration of hepatocellular carcino

78 plantation success was defined as successful vascular access, deployment of a single device in the pr

79 Midlines are a type of vascular access device (VAD) used exclusively in one tre

80 g multiple strategies (stakeholder meetings, vascular access device form, education sessions, ward ch

81 erted central catheters (PICCs) are a common vascular access device used in clinical practice.

82 ed with MCs when determining the appropriate vascular access device.

83 Vascular access devices (VADs) are frequently used in pa

84 h both solid and hematologic cancers require vascular access devices (VADs) for systemic chemotherapi

85 Vascular access devices can be divided into external cat

86 bosis are serious complications of long-term vascular access devices in children undergoing chemother

87 complications during dwell time, additional vascular access devices required to complete treatment,

88 001), and fewer patients required additional vascular access devices to complete treatment in the MC

89 gastrostomy, 3.1% new tracheostomy, 0.6% new vascular access devices, 0.4% new ostomy procedures, and

90 stomy placement, gastrostomy tube placement, vascular access devices, ostomy procedures, and amputati

91 g and are among the most heavily manipulated vascular access devices.

92 Mortality for delays due to difficult vascular access, difficulty crossing a lesion, and other

93 lysis care disparities strengthened incident vascular access disparity and the attributable associati

94 patients, a stented vessel was utilized for vascular access during subsequent cardiac surgery (n = 3

95 tula (AVF) of hemodialysis patients leads to vascular access dysfunction and inadequate hemodialysis.

96 Vascular access dysfunction compromises the care of pati

97 Hemodialysis vascular access dysfunction contributes to increased mor

98 Vascular access dysfunction contributes to the mortality

99 Hemodialysis vascular access dysfunction is the single most important

100 ion failure is the primary cause of dialysis vascular access dysfunction.

101 ent kidney transplantation, delayed need for vascular access (especially in small children), reduced

102 led based on the commonality of the need for vascular access, extracorporeal blood volumes, and bedsi

103 racial disparities associated with premature vascular access failure after percutaneous access mainte

104 ications are frequent causes of hemodialysis vascular access failure and contribute considerably to t

105 able strategy to treat AV graft hemodialysis vascular access failure.

106 composite endpoint, all-cause mortality, or vascular access failure.

107 ogated the interaction between iron dose and vascular access (fistula versus catheter).

108 monitoring program using ultrasound dilution vascular access flow technology to direct referral for a

109 scular access flow using ultrasound dilution vascular access flow technology, on FO/HTN and VAT in th

110 atocrit-guided ultrafiltration algorithm and vascular access flow using ultrasound dilution vascular

111 d hospitals of adult patients who required a vascular access for > or = 2 weeks.

112 , the mechanism is more complex than site of vascular access for BAS or exposure to central venous ca

113 CIPANTS: The Routine Ultrasound Guidance for Vascular Access for Cardiac Procedures (UNIVERSAL) rando

114 uency, eight on dialysis accuracy, and 22 on vascular access for dialysis INTERPRETATION: Most patien

115 sease are often dehydrated and need adequate vascular access for fluid resuscitation, nutrition, and

116 However, options for chronic vascular access for haemodialysis - an essential part of

117 r renal replacement therapy who had incident vascular access for HD created between January 1, 2006,

118 Arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis (HD).

119 teriovenous fistula is the preferred type of vascular access for hemodialysis because of lower thromb

120 enous fistula (AVF) is the preferred type of vascular access for hemodialysis but has high rates of d

121 nd an arteriovenous fistula as the preferred vascular access for hemodialysis, but quantitative assoc

122 enous fistula (AVF) is the preferred type of vascular access for maintenance haemodialysis but it may

123 Background Vascular access for ongoing hemodialysis often fails, fr

124 nneled catheters are an alternative means of vascular access for patients in need of hemodialysis who

125 The Tesio catheter is a reasonable means of vascular access for patients who undergo dialysis but ar

126 provement efforts, and advance the safety of vascular access for patients with cancer.

127 (CVAP) are widely used to provide long-term vascular access for the delivery of chemotherapeutic med

128 al to the nephrologist, and use of temporary vascular access for the first dialysis.

129 versus 17%) or have a functioning permanent vascular access for the first hemodialysis (40% versus 4

130 7 (95% CI, 0.75-0.80) for receiving incident vascular access, for a 23% lower rate.

131 Thrombosis of hemodialysis vascular access grafts represents a major medical and ec

132 Uniform vascular access guidelines for elderly patients may be i

133 is patients with central venous catheters as vascular access had their ScvO2 monitored during a 6-mon

134 Hemodialysis vascular access has emerged as a major cause of patient

135 ity of this preventive approach to long-term vascular access has not been established.

136 nous fistulas placed surgically for dialysis vascular access have a high primary failure rate resulti

137 S-ICD may be ideal for patients with limited vascular access, high infection risk, or some congenital

138 Models controlled for vascular access history, patient socioeconomic status, a

139 s the initial access followed by a synthetic vascular access if the AVF did not mature compared to (2

140 n-related hospitalization was related to the vascular access in 21% of the cases, and non-access-rela

141 o have exhausted all options for a permanent vascular access in both upper extremities.

142 ntraosseous route provides fast and reliable vascular access in emergency medical situations.

143 teriovenous fistulae are the optimum form of vascular access in end-stage renal failure.

144 includes exceptionally high use of surgical vascular access in Japan and in some European countries,

145 m in September 2003, a new classification of vascular access in patients who were candidates for bowe

146 Loss of vascular access in patients with intestinal failure is c

147 ta characterizes the profile of hemodialysis vascular access in the United States and identifies dete

148 analyzed; outcomes of interest were type of vascular access in use (fistula vs. graft) in hemodialys

149 en though catheters represented only 7.6% of vascular accesses in the study.

150 Haemodialysis provides various options for vascular access, including native arteriovenous fistulas

151 are likely to be multifactorial and include vascular access infection, less-than-sterile dialysate,

152 tion of practice guidelines for hemodialysis vascular access into national CPMs, there is substantial

153 Placement of right atrial catheters for vascular access is a common operative procedure.

154 Vascular access is a principal cause of morbidity and co

155 Establishing vascular access is critical for administering guideline-

156 Achieving reliable vascular access is crucial for optimizing experimental o

157 neal dialysis, kidney transplant, or current vascular access is failing.

158 The ability to gain vascular access is often impaired because of large body

159 ispanic ethnicity, non-arteriovenous fistula vascular access, lack of predialysis nephrology care, an

160 f ECLS included veno-venous or veno-arterial vascular access, lung "rest" at low FiO2 and inspiratory

161 l wall of the internal jugular in a lifelike vascular access mannequin in the majority of cases.

162 d that the maintenance and placement of ESRD vascular access may account for up to 25% of the ESRD bu

163 Reoperations are frequent; peripheral vascular access may be compromised and sternal reentry i

164 egarding risks/benefits associated with each vascular access (mean knowledge score 3/5 (95% confidenc

165 estigational site, surgical risk cohort, and vascular access method, to transcatheter aortic valve re

166 The vascular access monitoring program using ultrasound dilu

167 Frequent hemodialysis requires using the vascular access more often than with conventional hemodi

168 Component blocks include large bore vascular access, navigation within the left atrium, occl

169 lt hurdles, and truly creative approaches to vascular access need resources that include well-designe

170 logist, according to National Association of Vascular Access Networks guidelines, and the initial PIC

171 Vascular access nurses and their perceived role as part

172 ge (93%) of valued consultants reported that vascular access nurses placed the majority of PICCs at t

173 This sample was further restricted to vascular access nurses who worked in a U.S. hospital (n=

174 We examined vascular access nurses' perceived role related to use of

175 The presence and proliferation of vascular access nursing in hospital settings has been id

176 Clotting of the vascular access occurred in two patients when the dose o

177 Clinician's recommendations for vascular access often do not sufficiently consider the u

178 s an individualized approach to hemodialysis vascular access, on the basis of each patient's unique b

179 Vascular access options in coronary angiography can be c

180 g static (vs dynamic) ultrasound guidance of vascular access or the use of needle guide devices.

181 ct arteries and/or veins in vascular bypass, vascular access, organ transplant, and reconstructive su

182 The primary vascular access outcome was time to first access event (

183 outlines the financial barriers to improved vascular access outcomes and our proposals for a future

184 s fistula (AVF) maturation failure, and poor vascular access outcomes in this population.

185 sults underscore the importance of including vascular access patency in future studies of BP manageme

186 allowed us to identify the first predialysis vascular access placed rather than the first access used

187 all-cause mortality outcomes based on first vascular access placed, considering the fistula group as

188 are claims to identify the first predialysis vascular access placed.

189 other countries) and noted less emphasis on vascular access placement compared with surgeons elsewhe

190 of the 70 patients who underwent mapping had vascular access placement.

191 In addition, CT-based vascular access planning has been shown to reduce vascul

192 e, present arguments why SDM is necessary in vascular access planning, review barriers and potential

193 , SDM is not broadly applied in hemodialysis vascular access planning.

194 f CVC dysfunction will inform individualized vascular access plans, targeted use of preventive strate

195 flows may frustrate sugar export: one at the vascular access point and the other at the endodermis.

196 A head-mounted vascular access point eliminates the need for a back-mou

197 Subcutaneous vascular access port patency was maintained up to 136 da

198 Subcutaneous vascular access ports were surgically placed in each mon

199 this article we review the current state of vascular access practice, present arguments why SDM is n

200 In hemodialysis vascular access practice, SDM advocates a deliberative a

201 articipative decision-making in hemodialysis vascular access practice.

202 Initial attempts were complicated by vascular access problems and lack of appropriate tools.

203 proach to AVF placement reduces frequency of vascular access procedures and cost of access management

204 respecified end points included frequency of vascular access procedures, access management costs, and

205 ed survey was administered to members of two vascular access professional organizations.

206 A vascular access PtDA for eligible patients undergoing co

207 One hundred fifty patients were randomized (vascular access PtDA=76 versus usual care=74).

208 better informed value congruence with their vascular access received (47.3% versus 25.7%, P<0.01).

209 < .05) associated with having a catheter for vascular access; receiving treatment on a Monday, Wednes

210 or patient demographics, months on dialysis, vascular access, recently treated infections, signs and

211 These include noncompliance, vascular access recirculation, and dialyzer dysfunction.

212 Hemodialysis vascular access recommendations promote arteriovenous (A

213 atening TPN complications, including lack of vascular access, recurrent line infections, and intermit

214 In this study, we assessed the occurrence of vascular access-related complications in EP procedures w

215 ar, infection-related, fracture-related, and vascular access-related hospitalization.

216 M was associated with higher nonvascular and vascular access-related hospitalizations and mortality c

217 e in serum albumin levels or ACM, or all non-vascular access-related hospitalizations.

218 even (53.8%) of the 13 patients with primary vascular access-related infections had concurrent metast

219 asked with recommending measures to decrease vascular access-related infections.

220 plasma total homocysteine (tHcy) levels and vascular access-related morbidity was examined in a coho

221 These results suggest that vascular access-related outcomes may be optimized by con

222 he maintenance and longevity of hemodialysis vascular access remains one of the most problematic topi

223 ortic root, coronary arteries, and potential vascular access routes.

224 designed to identify potential predictors of vascular access site (VAS) complications in the large-sc

225 The vascular access site complication rate was 1.5%.

226 ated with a 0.40% absolute risk reduction in vascular access site complications (95% confidence inter

227 e cumulative incidence of major bleeding and vascular access site complications at 30 days.

228 effectiveness of ACDs for the prevention of vascular access site complications in patients undergoin

229 The rate of vascular access site complications was 9.3% in the enoxa

230 The main outcome measure was vascular access site complications, and nonaccess site b

231 Vascular access site complications, particularly those d

232 perforation, device dislocation, and femoral vascular access site complications.

233 Adverse bleeding events, largely related to vascular access site hemorrhage, were slightly increased

234 nced a major hemorrhage, which occurred at a vascular access site in six patients.

235 The association between femoral arterial vascular access site management (manual pressure [includ

236 The vascular access site was predominantly transradial in th

237 3019 randomly assigned patients with a known vascular access site, 2358 received ALPS drugs intraveno

238 Major bleeding at the vascular access site, hemolysis, and pericardial tampona

239 k of bleeding, particularly from the femoral vascular access site, may be reduced through the use of

240 njury (AKI) after PCI might be influenced by vascular access site.

241 eding complications seem to relate mainly to vascular/access site complications (related to the use o

242 oninferior to manual compression in terms of vascular access-site complications and reduced time to h

243 Vascular access-site complications occurred in 4 patient

244 oninferior to manual compression in terms of vascular access-site complications.

245 n models: 1) clinical factors; 2) clinical + vascular access strategies (femoral vs. radial, use of c

246 model was implemented to compare 2 different vascular access strategies among incident dialysis patie

247 ug therapy, the use of an intraosseous-first vascular access strategy did not result in higher 30-day

248 an AVF or AVG, we compared a less selective vascular access strategy of maximizing AVF creation with

249 f an intraosseous-first or intravenous-first vascular access strategy.

250 as associated with a 10% increase in odds of vascular access surgery (95% confidence interval, 8% to

251 Upper extremity vascular access surgery using polytetrafluorethylene (PT

252 t mature compared to (2) placing a synthetic vascular access (SVA1st) as the initial access device.

253 entified, including the protective aspect of vascular access team insertion, and high catheter failur

254 Catheters inserted by vascular access teams were less likely to dislodge (HR 0

255 scribed time or blood flow rates followed by vascular access testing.

256 Arteriovenous fistulas are the ideal form of vascular access that allows provision of haemodialysis.

257 ertension (9%), anemia (9%), infection (7%), vascular access thrombosis (2%), stroke (2%), and bowel

258 ere fluid overload/hypertension (FO/HTN) and vascular access thrombosis (VAT).

259 There were 2005 total episodes of vascular access thrombosis during a median 3.1 years of

260 able risk factors to reduce the incidence of vascular access thrombosis in hemodialysis could reduce

261 Our primary outcome measure was episodes of vascular access thrombosis occurring within a given 6-mo

262 cardiovascular events, hospitalizations, and vascular access thrombosis, respectively.

263 ystolic BP associate with increased rates of vascular access thrombosis.

264 olic BP were associated with higher rates of vascular access thrombosis.

265 Vascular access thrombotic episodes were recorded over a

266 Overall, participants achieved faster vascular access times with sonic flashlight guidance (P

267 e in the United States rely on a functioning vascular access to provide life-sustaining hemodialysis,

268 it is time for the practice of hemodialysis vascular access to shift from a hierarchical doctor-pati

269 Hemodialysis requires reliable vascular access to the patient's blood circulation, such

270 After propensity score matching, the median vascular access-to-balloon time was 4 to 6 minutes short

271 ith a statistically significant reduction in vascular access-to-balloon time, although the 4- to 6-mi

272 ent with conventional US performed simulated vascular access trials on three tasks with the sonic fla

273 with no US experience performed 60 simulated vascular access trials with sonic flashlight or conventi

274 <60 mg(2)/dl(2)), dose (Kt/V > or =1.2), and vascular access type (fistula); hospitalization rates; a

275 United States and identifies determinants of vascular access type 2 yr after the translation of vascu

276 lysis, but quantitative associations between vascular access type and various clinical outcomes remai

277 data describing study design, participants, vascular access type, clinical outcomes, and risk for bi

278 Gender, body mass index, weight, vascular access type, length, site, and mode of continuo

279 A recent national survey of vascular access types among incident American hemodialys

280 nd cardiovascular events compared with other vascular access types, and patients with usable fistulas

281 ident vascular access and 62.00% of maturing vascular access underuse.

282 Incident vascular access use rates and mortality.

283 s for chronic kidney disease (CKD) relies on vascular access (VA) devices, such as arteriovenous fist

284 th an arteriovenous fistula, but the role of vascular access (VA) type in the morbidity and mortality

285 ol for angiographic- and fluoroscopic-guided vascular access was associated with a low rate of vascul

286 Intraosseous vascular access was easily established in all animals, a

287 In study 3, sonic flashlight-guided vascular access was gained in the cadaver.

288 Although ultrasound training in vascular access was nearly universal, training in other

289 n section to avoid steroid-induced abortion; vascular access was obtained, and the fetuses were venti

290 Rats were anesthetized with halothane and vascular access was obtained.

291 Vascular access was transfemoral (n = 35), subclavian (n

292 d, and angiographic- and fluoroscopic-guided vascular access was used for Impella implantation in all

293 Vascular access was via the left axillary vein.

294 15%, respectively, and claims for permanent vascular access were found for only 30% of hemodialysis

295 al to the nephrologist and lack of permanent vascular access were independently associated with incre

296 No complications related to the device or vascular access were observed during follow-up.

297 Learning and performance of vascular access were significantly faster with the sonic

298 a 'one-size-fits-all' approach for effective vascular access will be feasible in the current environm

299 access time over trials) did not differ for vascular access with sonic flashlight and conventional U

300 omplications rate was low, mostly related to vascular access, with no patients requiring urgent manag